Literature DB >> 3046020

Therapeutic approaches in mixed cryoglobulinemia.

D Geltner1.   

Abstract

In summary, one can say that, although EMCG is a perplexing and puzzling disease, and although there are more enigmas than solutions, we can establish a way of handling the disease, knowing how to divide it into benign or acute forms, and establishing a treatment attitude according to that knowledge. PP and its modifications, in combination with immunosuppressive agents, are the corner-stones to the acute form of the disease complicated by vasculitis, nephritis, chronic hepatitis and CNS involvement. Looking ahead, a new and more specific mode of treatment could emerge from our and others observations that the IgMs in the mixed cryoproteins are antiidiotypes to the IgGs. By producing autoantiidiotypes it might be possible to block some of the immune complex formation and to interfere with the cold precipitation, which is the basic pathophysiological process of essential mixed cryoglobulinemia.

Entities:  

Mesh:

Year:  1988        PMID: 3046020     DOI: 10.1007/BF02054027

Source DB:  PubMed          Journal:  Springer Semin Immunopathol        ISSN: 0344-4325


  50 in total

1.  Treatment of the renal involvement in mixed cryoglobulinemia with prolonged plasma exchange.

Authors:  C Ferri; L Moriconi; G Gremignai; P Migliorini; G Paleologo; P V Fosella; S Bombardieri
Journal:  Nephron       Date:  1986       Impact factor: 2.847

Review 2.  Cryoimmunoglobulins.

Authors:  H M Grey; P F Kohler
Journal:  Semin Hematol       Date:  1973-04       Impact factor: 3.851

3.  Interrelations of the renal kallikrein-kinin system and renal prostaglandins in the conscious rat. Influence of mineralocorticoids.

Authors:  A Nasjletti; J C McGiff; J Colina-Chourio
Journal:  Circ Res       Date:  1978-11       Impact factor: 17.367

Review 4.  Therapeutic plasma exchange.

Authors:  K H Shumak; G A Rock
Journal:  N Engl J Med       Date:  1984-03-22       Impact factor: 91.245

5.  Use of anti-idiotypic antibodies to demonstrate rheumatoid factor producing bone marrow cells in essential mixed cryoglobulinaemia.

Authors:  A E Gharavi; G Campion; G R Hughes
Journal:  Ann Rheum Dis       Date:  1984-08       Impact factor: 19.103

6.  Cryoglobulin removal with cryofiltration in the treatment of cryoglobulinemia.

Authors:  Y Abe; H Sakamoto; T Matsugane; K Okabe; T Takaoka; E Blasutig; J W Smith; P S Malchesky; Y Nose
Journal:  Trans Am Soc Artif Intern Organs       Date:  1984

7.  Use of plasmapheresis and partial plasma exchange in the management of patients with cryoglobulinemia.

Authors:  E M Berkman; J B Orlin
Journal:  Transfusion       Date:  1980 Mar-Apr       Impact factor: 3.157

8.  Evidence for a therapeutic effect of plasmapheresis in patients with systemic lupus erythematosus.

Authors:  J V Jones; R H Cumming; P A Bacon; J Evers; I D Fraser; J Bothamley; C R Tribe; P Davis; G R Hughes
Journal:  Q J Med       Date:  1979-10

9.  Intravenous methylprednisolone pulse therapy in essential mixed cryoglobulinemia nephropathy.

Authors:  A De Vecchi; G Montagnino; C Pozzi; A Tarantino; F Locatelli; C Ponticelli
Journal:  Clin Nephrol       Date:  1983-05       Impact factor: 0.975

10.  Inhibtion of cold insolubility of serum cryoglobulin by epsilon aminocaproic acid.

Authors:  P Lalezari; M Kumar
Journal:  Am J Med       Date:  1980-04       Impact factor: 4.965

View more
  1 in total

Review 1.  Treatment of vasculitis.

Authors:  H G Taylor; A Samanta
Journal:  Br J Clin Pharmacol       Date:  1993-02       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.